The drug is currently being evaluated in three late-stage clinical trials, with a lead indication for prevention of stroke and systemic embolism in patients with irregular heart rhythm known as ...

Overall, however, the net clinical benefit—based on an endpoint incorporating all stroke and systemic embolism, MI, cardiovascular death, and major bleeding—tends to lean toward giving the DOAC versus ...

Future Cardiol. 2012;8(6):847-861. The benefits of surgery to prevent embolism are therefore greatest at an early stage, deferral of surgery for 2–3 weeks for this indication alone is of little ...